Alembic Pharmaceuticals has received an Establishment Inspection Report from the US health regulator for its formulation facility located at Panelav in Gujarat.
“The company has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at our formulation facility at Panelav during the period from March 12-20, 2018,” Alembic Pharmaceuticals said in a BSE filing today.
USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
Shares of Alembic Pharma were trading up by 2.98 per cent at Rs 521.65 on the BSE.